Phase II study of Gemcitabine + nab-paclitaxel as first-line therapy for locally advanced pancreatic cancer
Phase 2
- Conditions
- locally advanced unresectable pancreatic cancer
- Registration Number
- JPRN-UMIN000016852
- Lead Sponsor
- Kurume university school of medicine
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 24
Inclusion Criteria
Not provided
Exclusion Criteria
1) Patients with Distant metastasis 2) Patients with symptomatic pulmonary fibrosis or interstitial pneumonia 3) Patient has active, uncontrolled bacterial, viral, or fungal infection(s) requiring systemic therapy. 4) Patients has severe complications, such as heart failure, renal failure ileus and severe mental disorder 5) History of malignancy in the last 3 years 6) History of Peripheral Artery Disease (eg, claudication, Leo Buerger's disease). 7) History of connective tissue disorders (eg, lupus, scleroderma, arteritis nodosa). 8) Women who are pregnant or expect to be pregnant, or nursing female 9) Others
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Response rate
- Secondary Outcome Measures
Name Time Method Overall survival, progression free survival, adverse events